32results about How to "Maintain specificity" patented technology

The present invention relates to the anti-human hepatocarcinoma McAb HAb18 heavy chain and light chain variable region genes, the polypeptides encoded by the same, as well as to their use in the preparation of a medicament for diagnosing and treating tumors or inflammation diseases. Based on the heavy chain and light chain variable region genes, various novel small molecule genetic engineering antibodies, including single chain antibodies, chimeric antibodies, Fab antibodies and the like can be constructed and expressed for the diagnosis and treatment of hepatoma.

The invention provides reagents and methods for multivalent binding and quantitative capture of components in a sample. In one aspect, reagents and methods for diagnostic assay for antigen, ligand, binding agent, or antibody are provided. Compositions of a non-natural or deliberately constructed nucleic acid-like polymeric scaffold are provided, to which multiple antibodies, peptides or other binding agents can be affixed by hybridization of a oligonucleotide: binding agent complex such that the nucleic acid: binding agent construction displays multivalent behavior when interacting with a multivalent analyte. Methods for constructing and using the scaffolds are described. Such compositions may include assembly of mixed specificity binding agents such that the composition displays multivalent binding behavior against a target containing mixed analytes which can be bound by the construct to effect a binding affinity increase such as is observed in avidity reagents against single analytes expressed multiply on the target analyte. A manufacturing method for producing rapid diagnostic assays in a decentralized manner is also described. The method generates net economic advantages over conventional diagnostic manufacturing practices.

Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans.

The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

The invention provides cells and methods for identifying modulators of signal transduction, based on transducisome proteins that coordinate and assemble many types of signal transduction proteins. A transducisome is a PDZ domain containing protein that binds at least one signal transduction protein or a PDZ domain containing protein with at least one signal transduction protein bound. Examples of transducisome proteins include INAD, GRIP and other recently identified multi-PDZ domain proteins. Examples of signal transduction proteins include GPCRs, tyrosine kinase receptors, tyrosine phosphatase receptors, ion channels, phospholipases, adenylate cyclases, kinases and G-proteins. Also provided are methods for identifying modulators of signal transduction, proteins (and polynucleotides encoding the same) corresponding to transducisomes, modified transducisomes or defective transducisomes to use in assays of signal transduction, and a screening assay system for detecting protein-protein interactions.

The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

Described herein are approaches for the improved detection, identification, and / or quantification of target nucleic acids. These approaches provide a means of detecting, identifying, and / or quantifying rare target nucleic acid molecules, including DNA and RNA molecules, from the same sample, and in the same reaction, by using “hairpin barcode primers,” as the term is defined herein, to incorporate unique barcodes into target nucleic acids in a PCR pre-amplification step.

The invention discloses a tissue culture and rapid propagation method for variation malus spectabilis, and belongs to the field of plant tissue culture and propagation. The tissue culture and rapid propagation method has the advantages that processes for explant selection and disinfection, primary culture, secondary culture, rooting culture, transplanting and the like in variation malus spectabilis tissue culture are provided, accordingly, the contamination rate of the variation malus spectabilis tissue culture and the death rate of tissue culture seedlings due to improper handling can be reduced, and the variation malus spectabilis tissue culture efficiency can be improved.

The present invention relates to the anti-human hepatocarcinoma McAb HAb18 heavy chain and light chain variable region genes, the polypeptides encoded by the same, as well as to their use in the preparation of a medicament for diagnosing and treating tumors or inflammation diseases. Based on the heavy chain and light chain variable region genes, various novel small molecule genetic engineering antibodies, including single chain antibodies, chimeric antibodies, Fab antibodies and the like can be constructed and expressed for the diagnosis and treatment of hepatoma.

The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Disclosed is polynucleotide encoding a polypeptide comprising an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as polypeptides having such properties and uses of such polypeptides in detecting and treating HCV infection.

The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more of the novel imaging agents of the invention.

The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

The present invention relates to a novel method for an accurate quantification in intestinal samples of Faecalibacterium prausnitzii phylogroup I members (PHGI) and / or Faecalibacterium prausnitzii phylogroup II members (PHGII). It further relates to a method for detecting intestinal diseases, including the screening, diagnosis, differential diagnosis, and / or monitoring of disease activity or progression in a human subject comprising determining the abundance of PHGI and / or PHGII in an intestinal sample from said subject. Moreover, it relates to a method for the prediction of the efficacy of a drug in the therapeutic treatment of an intestinal disease in a human subject comprising determining the abundance of PHGI and / or PHGII in an intestinal sample from said subject.

The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.

The invention provides a method for preparing a super-complex which comprises repeat-chains containing single or multiple kinds of monomer-specific protein binding domains having at least two binding sites for a monomer repeated therein; preparing single complexes of the repeat-chains and a protein monomer having at least two binding sites for the monomer-specific binding domain of the repeat-chains, by mixing the repeat-chains and the protein monomer, and then generating the super-complex by forming cross-binding between the single complexes of repeat-chains and the protein monomers.